



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/017,193	12/12/2001	Mai Huong Dang	NFCSNZ01200	5901
71536 7590 02/24/2009 Nfocus Neuromedical Inc., c/o Levine Bagade Han LLP 2483 East Bayshore Road Suite 100 Palo Alto, CA 94303				
EXAMINER PADGETT, MARIANNE L				
ART UNIT		PAPER NUMBER		
1792				
MAIL DATE		DELIVERY MODE		
02/24/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/017,193

Applicant(s)

DANG ET AL.

Examiner

MARIANNE L. PADGETT

Art Unit

1792

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11/20/2008 & 7/9/2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-7, 9, 11-24, 27, 28, 33 and 34 is/are pending in the application.
- 4a) Of the above claim(s) 11, 16-19, 27, 28 and 33 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-7, 9, 12-15, 20-24, 34 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

Art Unit: 1792

1. Applicants have requested rejoinder of claims 27 & 28 with the elected & examined claims, as they have amended independent claim 1 step (c) to positively require covalent attachment of "a surface modifying group having a terminal carboxylic acid group" to the stable functional group, and claim 27, from which 28 depends, requires "said multifunctional linker is a halogenated carboxylic acid", however the independent claim does not have any limitations to any "multifunctional linker", however the examiner notes that dependent claim 26 once provided such a connection, however they withdrawn claim 27 was not amended so as to stay consistent with the amended independent claim, so rejoining these claims at this time would not be appropriate.

2. **Claims 1-7, 9, 12-15, 20-24 & 34** are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In **claim 1** as amended, the relationship of "an agent" at the end of step (c) & "a bioactive or biocompatible agent" in step (d) is unclear, since "an agent" is not necessarily differentiated from the agent in step (d). The examiner notes that the added limitation concerning improved cell attachment appears to have been derived from the disclosure on page 10, lines 26-29 of the original specification that states: "In one embodiment the surface-modifying group 18 **is a carboxylic acid group** which may result in **increased fibronectin** and/or decreased albumin absorption, therefore improving cell attachment and proliferation on the substrate" (emphasis added), thus since fibronectin is apparently taught to increase (what some people might consider "improving" cell attachment) & could be considered in agent, where absorption may be considered being bound, it is unclear what is meant in light of the specification.

Use **relative terms** that lack clear metes and bounds in the claims or in a clear definition in the specification, or in relevant cited prior art, is vague and indefinite. In claim 1, step (c) has been amended to require "**improving cell attachment and proliferation**" (emphasis added), however "improving" does not specify what constitutes an improvement, since to some people have been less cell attachment and

Art Unit: 1792

less proliferation of cells may be desirable, while other people may find just the opposite desirable, hence what one considers an improvement is relative to ones desired and results, thus it is unclear what scope is actually intended by the claim of "improving...".

3. **Claims 1-7, 9, 12-15, 20-24 & 34** are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Given the disclosure in the specification which appears to teach that fibronectin is absorbed, thus bound on carboxylic acid groups & increases cell attachment, the "wherein the carboxylic acid group results in improved cell attachment and proliferation on the substrate when not bound to an agent" does not appear to be appropriately supported, as it appears to contradict teachings of the original specification.

Furthermore, computer search of the application's PGPub found no disclosure in the original specification of "a surface-modifying group having a terminal carboxylic acid group" or any use of the root words terminal or terminate. Disclosures in the original specification with respect to the use of carboxylic acid groups, or carboxylic acid in general were found on page 4, lines 8-15 ([0029] in PGPub) or page 9, lines 3 in 12 ([0064]) or original claim 7 directed to use of carboxylic acid in claim 1, step (a); and page 4, lines 28-31 ([0032]) or page 11, lines 29-37 ([0078]) or original claims 27-28 teaching multifunctional linker is consisting of halogenated carboxylic acid; and the above noted disclosure on page 10 ([0073]), where the carboxylic acid I the surface modifying group, not a ligand thereon, terminal or otherwise.

For these reasons, the independent claim 1 as amended appears to encompass New Matter, since "a surface-modifying group having a terminal carboxylic acid group" is broader than the scope of the original disclosure, as it includes options other than the originally disclosed surface modifying group is a carboxylic acid group, or the originally disclosed multifunctional linker which is a halogenated carboxylic

Art Unit: 1792

acid, where of these two specific taught options, only the latter is a very specific species of what is now claimed, i.e. not sufficiently broad to suggest the new amended claim language; while a surface modifying group that is a carboxylic acid group does not appear to be properly or necessarily included in the present claim language as written, hence also does not suggest the amended claim language.

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(c), (f) or (g) prior art under 35 U.S.C. 103(a).

The **nonstatutory double patenting rejection** is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Art Unit: 1792

5. **Claims 1-5, 7, 9, 12, 20-24 & 34** are rejected under **35 U.S.C. 103(a)** as being unpatentable over **Subramanian** (5,643,580) in view of **Kunz et al** (6,733,847 B2), optionally further in view of **Spence et al.** (6,106,659), or optionally **Inagaki et al.** (2002/0098296 81), or optionally **Rudakov et al.** (2009/0043375 A1).

Subramanian ('580) teach plasma treating a surface to functionalize it, where that surface may be part of medical device, such as a catheter, vascular stents or various blood transfer devices, hence includes tubular substrates with lumen as well as plastic surfaces. The plasma is used to break bonds & create reactive groups, and if a reactive gas is employed which reacts with the substrate, then functional groups, such as hydroxyl or carboxyl or amine, are formed on the surface via use of gas mixtures, such as CH_4/O_2 or $\text{H}_2\text{O}/\text{O}_2$ or CH_4/NH_3 , where it is taught that the reactive gases may also be introduced with an inert carrier, such as He or Ar, typically in a 3:1 ratio (col. 3, lines 10-16). The reactive groups may then be modified by or further functionalized with an amphipathic compound (i.e. multifunctional linker) and a bioactive agent, either simultaneously or in sequence, where bioactive agents may include antithrombogenic compounds (heparin) or polypeptides (amino-acid sequences) or antibiotics or growth factors, etc (reads on either step I(d) or I(d)+I(c)), and where cross-linking agents are noted to be used to covalently link between surface and bioactive agents. See the abstract; summary, esp. col. 1, lines 20-56; col. 2, lines 44-60; col. 3, line 1- col. 4, line 35, esp. col. 3, line 4-30 for gases and reactive groups, lines 31-50 for step sequences and lines 52-64 for uses with col. 4 discussing substrates; col. 5, lines 1-29 for a particular example with xylose ($\text{CH}_2\text{OH}(\text{CHOH})_3\text{CHO}$) is reacted with carboxyl groups on the plasma treated surface by an estrus location process in the presence of 1-ethyl- 3-(3- dimethylaminopropyl) carbodiimide (e.g. reacting with a multifunctional group), then heparin as a biological surface modifying agent is covalently bound thereto. **Subramanian** ('580) provide additional examples (column 6, lines 1- 13: plasma treated surface appears to be covalently bonded via cross-linking within LB deposited glutamate copolymer that has carboxylic terminus, which is then derivative iced with a layer of himdin),

Art Unit: 1792

which would have indicated to one of ordinary skill in the art that choice of particular functional groups at each stage is dependent on specific chemistry of the desired final bioactive layer. While the exemplary deposition sequences of the primary reference do not follow the explicit sequence of steps of plasma treating, then non-plasma exposing to claimed gas or liquid is, then contacting with a group (e.g. compound) having a terminal carboxylic acid group, followed by contacting/binding with a bioactive/biocompatible agent, the teachings are suggestive of employing all the sequential steps, as carboxyl groups teachings are equivalent of carboxylic acid group teachings, and appear to be employed as a linking group in an equivalent stage of attaching an Bio-agent to the treated surface, such that one of ordinary skill in the art would have considered using terminal carboxylic acid, e.g. carboxyl terminus, as the means for attaching compatible bio-agents in any of the optional taught sequences, dependent on the specific chemistry involved. **Alternatively**, given these teachings & considerations, it would've been further obvious to one of ordinary skill in the art considering the optional reference of Rudakov et al. (2009/0043375 B1, effective filing date 8/22/2001), with further teachings on enhancing endothelial cell growth on polymer surfaces the use of sequences of plasma cleaning/plasma deposition/rinsing/covalent linker attachment/Bio-agent coating (abstract; figure 9-10; [0035-46], where the covalent linkers are inclusive of use of "linkers... ended with COOH groups... The COOH. groups can also form an ester linkage with COOH groups in the anticoagulant agent heparin..." [0046] of Rudakov et al. (375), which is considered cumulative to the above rejection, and would have been explicitly suggestive to one of ordinary skill the of the usefulness & effectiveness of attaching heparin via use of carboxylic acid terminal groups on linking molecules, which would've been relevant to suggested and uses of the primary reference.

For the plasma functionalization step, Subramaniam recommends using a low temperature plasma produced by glow discharge, where the "typical" pressures are 0.1-10 Torr, and also notes that the plasma breaks bonds, which teachings can be employed in alternative routes to produce the same desired end of

Art Unit: 1792

covalently bonding therapeutically effective coatings. Notably, the two main routes discuss either employing a reactive gas to react with the plasma broken bonds on the substrate, exemplified by reactive gas mixed with carrier gas in the plasma (col. 2, lines 56-col. 3, lines 30; col. 5, lines 3 and 29+), or exemplified by functionalizing via contact within amphoteric solution using Langmuir-Blodgett (LB) coating techniques, then crosslinking with inert gas plasma, where this latter techniques may also have had a first plasma functionalizing procedure to create reactive functional groups (-COOH, -OH, amines, etc.) before the LB deposition (col. 3, lines 32-40+; col. 6, lines 24-27).

Subramanian differs by not using an atmospheric pressure plasma, and by directly using the activated sites created by the plasma to covalently bond with surface modifiers equivalent to applicants' steps (c) &/or (d). While Subramanian teaches low-pressure as typically used, he does not teach that the pressure is critical to the plasma process, but emphasizes as important the glow discharge's ability to create reactive surface sites to enable functionalization of the surface, hence one of ordinary skill in the art would have expected that any plasma techniques, particularly a glow discharge plasma techniques, capable of such reactive site formation with resulting functionalization, would have been expected to be effectively employed in Subramanian's process, thus an obvious variation thereof.

Kunz et al teach treating various substrates, including many types of polymers (polyolefins, halogenated polymers, Teflon coated paper products, etc.), that may have various forms, such as films, molded, extended, fibers, felts, woven fabrics, etc. (col. 3, line 42- col. 6, line 67). The first step may be subjecting the substrate to plasma or glow discharge at atmospheric pressure, where the gas may be a mixture of inert gas with reactive gases, such as N₂, O₂ or H₂O, with use of a closed system when air is to be excluded. Note inert gases are by definition noble gases & Kunz et al. teaches primary plasma gasses inclusive of He, Ar & Xe (col. 2, lines 62-63), thus effectively suggesting combination of these gases with reactive gases. The next step after the discharge is discontinued, is applying as vapor or in solution, an electron- or H-donor to react with the free radical formed on the surface, that may be exemplified by

Art Unit: 1792

amines. Kunz et al. notes that for atmospheric conditions of corona discharge, the application of the H- or electron- donor group (i.e. functional group) can be applied by solution spraying, preferably after & downstream from the discharge zone. Thereafter, a further material (coating) may be applied, or the plasma treated & functionalize substrate may be stored. See the Abstract; col. 2, line 30- col. 3, line 19; col. 7, line 13-25+; col. 9, line 51- col. 10, line 18, especially lines 12-13; and col. 17, line 43- col. 18, line 36.

While specific mixes of gas preparation for the corona option are not taught, it would have been obvious to one of ordinary skill in the art to determine desirable proportion depending on specific materials being treated and required degree of surface functionalization for the particular end use, especially considering the teachings that "The process can be carried out under corona discharge conditions. **Corona discharges** are produced under **normal pressure conditions**, the ionized gas at used most frequently being **air**. In principle, however, other gases are also possible... When a corona discharge in an **open apparatus** is used, it is preferable to carry out the operation with the exclusion of oxygen, which can be achieved with a sufficient sufficiently large flow of **inert gas**" (emphasis added, col. 3, lines 3-19). Note that "normal pressure conditions" are considered equivalent to atmospheric pressure conditions, and that air comprises claim that noble gases, as well as the other taut alternative of slowing inert gases, thus applicants' arguments (paragraph bridging page 8-11 of 7/9/08 response) that Kunz et al. do not teach noble gas at atmospheric pressure is clearly incorrect, which makes the argument against its presence in the reference combination also not convincing.

Kunz et al does not disclose any particular solvents to use when solutions are being applied to functionalize the activated surface, however as many of the e⁻ or H- donors (amines) are polar molecules, use of polar solvents, such as water, would have been an obvious option due to known solubility, thus obvious to employ due to expected effectiveness. Note as claimed the specifically listed gas or liquid does not have to be what is supplying the functional group; it just must supply the effective conditions. It

Art Unit: 1792

is further noted that amines & ammonium hydroxide or ammonia have related chemical reactions, with overlapping applicability in the teachings.

Therefore, given the teachings of Kunz et al., which show that glow discharge plasma treatment (subatmospheric pressure to atmospheric pressure) may be employed to former reactive surfaces, **including with use of inert (e.g. noble gases = Ar, He, Xe)**, that are subsequently functionalized with either gas or liquids that supply functional groups with electron or hydrogen donors, that are intended to be employed for bonding subsequent deposits to produce strong adherence; it would have been obvious to one of ordinary skill in the plasma art to employ the techniques of Kunz et al. for plasma surface treatments in Subramanian (inclusive of corona discharge type plasmas), with the expectation of analogously beneficial results, as the techniques are employed for like it adhesion purpose on like materials [(Subramanian: plastic or metal substrates, including fibrous; col. 3, lines 10-15; col. 4, lines 1-35, especially 20-25) & (Kunz et al.: col. 1, lines 16-21; col. 2, line 66-col. 3, line 2 & 42-col. 7, line 12, naming numerous classes of plastics, as well as inorganics like metal as effectively treated, plus shapes of fiber, woven fabric, 3-D shapes, etc.)]. With respect to the gas composition used for the initial plasma treatment to create reactive sites in this combination of Subramanian & Kunz et al., choice of specific gas composition would have depended on particular substrate material being treated, desired functional groups to be formed thereon & used for bonding particular linking &/or coating materials, noting **overlapping teachings concerning mixtures of inert gases with reactive gases**, where routine experimentation would have reasonably been expected when employed for optimizing for particular materials to have encompassed composition proportions as claimed, especially considering that a higher percentage of oxygen at lower pressures will be equal to in the absolute amount of reactive gas present to a smaller percentage at higher pressures.

Optionally, **Spence et al.** (659) also teach plasma surfaced treatment techniques, including high pressure plasmas that may be 1 atm, noting the advantages of atmospheric pressure plasmas that don't

Art Unit: 1792

need or involve expensive pressure control systems; that higher levels of oxygen &/or nitrogen can be obtained on the high-pressure RF plasma activated surface than with conventional corona treatment; & that use of the high-pressure glow discharge techniques reduces contamination potential. Spence et al. teach applicability to have wide variety of techniques & effects (modify or improve surface properties for wettability/hydrophilicity,... to improve it adhesion of other materials, etc.), including gases (Ar, He, O₂, air,... ammonia... acrylic acid...) & substrates (fibers, films or webs, woven or nonwoven or porous, of natural or synthetic polymers, it uses such as food packaging, etc.), which provide overlapping teachings with the primary reference, and where Spence et al. is teachings additionally including gas mixtures of inert (Ar or He) + reaction (7 % O₂), as useful for the plasma treatments, demonstrating the expected effectiveness of such proportions. Also note teachings that initial plasma exposure to create an activated surface may include simultaneous or sequential exposure to reactants, such as monomers for grafting, thus further demonstrating its expected effectiveness of subsequent reaction after application of atmospheric pressure plasma with gases as taught in Subramanian & as claimed, as well as the expected effectiveness of such plasmas for used to create active sites for further functionalization. In Spence et al., particular see the abstract; figures 14-16; tables 1-11; col. 6, line 8-col. 8, line 25, especially col. 7, lines 15-49 & 62-col. 8, line 10; col. 9, lines 25-68+; col. 15, lines 6-21; col. 17, line 31-col. 18, line 39; col. 21, lines 13-40; col. 23, lines 28-43; col. 24, lines 1-47. Thus Spence et al. provides further motivation & demonstrations of expected effectiveness for the above combination.

Optionally, with respect to alternatively claimed sequences of applied gases after plasma treatment, i.e. air or oxygen, **Inagaki et al.** (296) demonstrates plasma treatment of polymer surfaces (polypropylene) followed by exposure to air (oxygen containing) to functionalize with O-containing groups, is effective for creating surfaces capable of subsequent covalent bonding (abstract; [0013-16] & [0030-34]), thus it would've been further obvious to one of ordinary skill in the art to employ such a sequence for the production of taught carboxyl &/or hydroxyl functional groups, as it has been reasonably

shown to be an effective techniques in analogous processing. It is further noted that while the exemplary preferred plasma parameters are for reduced pressures, that these are not required, and that either Kunz et al. &/or Spence et al. have shown the effectiveness of high pressure (1 atm) for plasma surface activation of like materials with like gases, hence reduced versus atmospheric pressure would not have been expected to provide any obstacle to the expected effectiveness of this taught treatment sequence, only expected to effect the optimization for particular process parameters, such as gas proportions, employed at the different pressures.

6. **Claims 13-15** are rejected under 35 U.S.C. **103(a)** as being unpatentable over **Subramanian** (*580) in view of **Kunz et al.** (& optionally Spence et al. or Inagaki et al., or Rudakov et al. (375 A1)), as applied to claims 1-5, 7, 9, 12, 20-24 & 34 above, and further in view of **Valentini** (6,428,579 B1) or **Clapper** (5,744,515).

While Subramanian does not elaborate on what is included by “growth factors” or protein options (col. 3, line 64), they consistently suggest that other bioactive agents than those they explicitly exemplify would have been usefully deposited by their technique (col. 2, line 51-55; col. 3, line 63-64; col. 6, lines 22-33), hence these teachings are considered suggestive of employing other biological agents that may influence or encourage growth or protein binding. Therefore, given teachings of desirable bioactive coating materials for cell growth, as in Valentini or Clapper discussed below, they would have been obvious for reasons given immediately below.

Valentini or Clapper teach claimed bioactive molecules for bonding proteins or cell attachments, such as proteins, collegian, fibronectin and laminin in the former, and fibronectin, P- or N-cadherin in the latter, hence as these specific species were known for use in the generic function as a cell adhesion agent, it would have been obvious to employ them in the teachings of Subramanian’s process for their know and intended function, as suggested by these ternary references. When employed in specific agents as suggested by Valentini or Clapper in the process of Subramanian (*580) in view of Kunz et al. (&

Art Unit: 1792

optionally Spence et al. or Inagaki et al.), it would've been further obvious to one of ordinary skill in the art to employ any of the suggested binding molecules, inclusive of suggested carboxyl group (e.g. carboxylic acid group) on linking groups/molecules, dependent on the specific chemistry of the particular bio-agent desired on the resulting surface.

7. **Claim 6** is rejected under 35 U.S.C. **103(a)** as being unpatentable over **Subramanian** ('580) in view of **Kunz et al.** (& optionally Spence et al. or Inagaki et al., or Rudakov et al. (375 A1)), as applied to claims 1-5, 7, 9, 12, 20-24 & 34 above, and further in view of **Ikeda et al.** (4,743,258) or **Clapper**.

Subramanian only discuss plastic substrates generally, thus does not discuss the specifically claimed porous expanded polytetrafluoroethylene, however either Ikeda et al. (abstract; col. 3, specially lined 32) or Clapper et al. (abstract; col. 7, line 55-col. 8, line 67+, specially lines 20-25), both previously cited/discussed, recite the usefulness of PTFE for vascular tubing, a type of enduse contemplated in Subramanian & expected to include porous structures, hence it would've been obvious to one of ordinary skill in the art to employ such materials as polytetrafluoroethylene for the plastic in such vascular prostheses the primary references processes, as it is seen to be a conventional plastic material used therefore in related processes were plasma treatment is also contemplated, especially considering that the secondary reference to Kunz et al. shows the expected effectiveness of plasma treating fluorocarbon surfaces, such as Teflon (PTFE), when sequential functionalization is to be performed (col. 5, lines 15-25 & col. 6, line 58).

8. **Claims 1-7, 9, 12, 21-23 & 34** are rejected under the judicially created doctrine of **obviousness-type double patenting** as being unpatentable over claims 1-8 and 11-17 of U.S. Patent No. **6,159,531** (Dang et al), in view of **Kunz et al** or **Spencer et al.** (659), as discussed above in section 4, and further in view of **Ikeda et al** (258) or **Clapper** in claims 3-6, as discussed above in section 7.

The broader claims of this application encompass the narrower claims of the patent, which is inclusive of use of multifunctional linkers with carboxylic acid groups thus consistent with amended claims, due to the broad terms in this application which encompass the narrower meaning is of the patented terms, which can be considered stable functional groups. The patent's claims are broader in that they are to a "plasma cleaning" technique, while employing claimed gases & analogously functionalizing the plasma treated surface, does not specify that the plasma is atmospheric pressure, nor that the cleaning technique necessarily creates active species on the surface of the substrate, however as shown by Kunz et al. or Spencer et al., atmospheric plasma treatments are known to be effective in creating such active sites for subsequent reaction to functionalize, including using the gases as required in the patented claims with separate non-plasma sequential reactions, demonstrating as discussed above the obviousness of employing atmospheric plasma where such surface activation is desired, as well as doing so with sequential functionalization.

The claims as presently written differ by the patent's claims which are more narrowly directed to a specific end use (medical devices), which is related to & overlapping with the present applications requirement of contacting & bonding a bioactive or biocompatible agent to the functionalize surface, which the patent also requires in its claims 2-3. The present independent application claim also differs by creating the functional groups in the absence of plasma, while the patented claims attach the functional groups by employing plasma to deposit a layer having functional groups, however this is an analogous difference with that of Subramanian, hence the reasons for combining with Kunz et al. are analogous thereto.

While the patent does not claim specific surface densities of bioactive or compatible agents, it would have been obvious to one of ordinary skill to adjust the degree of their treatments depending on the desired concentrations in the resultant product and end use, hence lacking any broad specific significance to the generic limitations, such is considered routine optimization.

The patent does not claim specific shapes or morphologies or PTFE substrates to be treated, however Ikeda et al or Clapper, discussed above shows the need and desirability to perform analogous treatments on tubular porous (PTFE) substrates as claimed, hence it would have been obvious to employ such substrates in the (531) patent process, as they have been demonstrated to be a type of medical device needing such treatments.

9. **Claims 13-15 & 20** are rejected under the judicially created doctrine of **obviousness-type double patenting** as being unpatentable over claims 1-8 & 11-17 of U.S. Patent No. **6,159,531** in view of **Kunz et al or Spencer et al.** (659), and further in view of **Ikeda et al** (258) or **Clapper** in claims 3-6, as applied above in section 9, and further in view of **Valentini** (6,428,579 B1) or **Clapper** (5,744,515), discussed in section 6 above.

The claims of this application encompass the narrower claims of the patent, due to the broad terms in this application which encompass the narrower meaning is of the patented terms, which can be considered stable functional groups.

While the patent claims, specifically 3, specify cell-adhesion agents, they do not enumerate specific ones as in claims 13-15, however, Valentini or Clapper teach claimed bioactive molecules for bonding proteins or cell attachments, such as proteins, collagen, fibronectin and laminin in the former, and fibronectin, P- or N-cadherin in the latter, hence as these specific species were known for use in the generic function as a cell adhesion agent, it would have been obvious to employ them in the ('531) process for their known and intended function, as suggested by these ternary references.

10. Also of interest are Rudakov et al. (6,371,980 B1 & 2009/0043375 B1), with further teachings on enhancing endothelial cell growth on polymer surfaces the use of sequences of plasma cleaning/plasma deposition/rinsing/covalent linker attachment/Bio-agent coating (figure 9, etc.), however does not disclose atmospheric plasma pressure, however is inclusive of use of "linkers... ended with COOH groups... The COOH groups can also form an ester linkage with COOH groups in the

Art Unit: 1792

anticoagulant agent heparin..." [0046] of (375), which is considered cumulative to the above rejection.

Also of interest, but not prior art are Cohen et al. (WO 2008/060522 82: abstract & cover figure) & Denes et al. (2008/0138626 A1).

Other references of interest to the state-of-the-art previously cited included: Zhang et al. (6,479,595 B1) that is equivalent to Spence et al. or Yializis et al for showing high pressure glow discharge treatments useful for surface functionalization, including atmospheric pressure, especially note col. 12, line 7-37 that teaches activity a plasma treated (functionalized) surface is stable with respect to air, but the teaching does not indicate whether or not any "conversion" occurs during such exposure to air.

Roth et al. (5,403,453), who is teaching use of atmospheric pressure plasmas to increase the wettability of a substrate surface, with the intent of producing a staple wettability of fact be a plasma that employs air, He, Ar, (He or Ar) + 7 % O₂.

Also employing atmospheric plasma surface treatments are: Timm et al. (6,787,179 B2), but all surface treatments therein are simultaneous, not multistep; Kuckertz et al. (6,613,394 B2), but employs a remote plasma & Bourham et al. (2007/0161308 A1), whose teachings are not prior art.

11. Applicant's arguments filed 11/20/2008 & 7/9/2008, and **discussed above** have been fully considered but they are not persuasive.

12. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Art Unit: 1792

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

13. **Any inquiry** concerning this communication or earlier communications from the examiner should be directed to **Marianne L. Padgett** whose telephone number is (571) 272-1425. The examiner can normally be reached on M-F from about 9:00 a.m. to 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Timothy Meeks, can be reached at (571) 272-1423. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Marianne L. Padgett/
Primary Examiner, Art Unit 1792

MLP/dictation software

2/16-17/2009